Although current GLP-1-based therapies for T2D and obesity are long-lasting, future work should focus on developing secretagogue-based therapies that will take advantage of the natural GLP-1 secretory rhythm. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.